{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:52:29Z","timestamp":1791337949382,"version":"4.3.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K01 CA245124-01"],"award-info":[{"award-number":["K01 CA245124-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA025874"],"award-info":[{"award-number":["P01 CA025874"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA010815"],"award-info":[{"award-number":["P30 CA010815"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA 182890"],"award-info":[{"award-number":["R01 CA 182890"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA047159"],"award-info":[{"award-number":["R01 CA047159"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA114046"],"award-info":[{"award-number":["P01 CA114046"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA221703"],"award-info":[{"award-number":["P50CA221703"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54 CA224070"],"award-info":[{"award-number":["U54 CA224070"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002224","name":"Melanoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017119","name":"Wistar Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017119","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.isci.2026.114669","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:14:45Z","timestamp":1768320885000},"page":"114669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dasatinib resensitizes BRAF\/MEK inhibitor efficacy in patient-derived xenografts from patients with progression on BRAF\/MEK inhibitor treatment"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8124-0900","authenticated-orcid":false,"given":"Vito W.","family":"Rebecca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kossenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetiana","family":"Godok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Schuyler","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Fingerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen M.","family":"Alicea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meihan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkai","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Portuallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vissy","family":"Elad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eneda","family":"Toska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell E.","family":"Fane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasey L.","family":"Couts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Nathanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerthana M.","family":"Arun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govind","family":"Warrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangfan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. N. Vashisht","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenhard","family":"Herlyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.114669_bib1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","article-title":"Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib","volume":"36","author":"Long","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.114669_bib2","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1470-2045(14)70301-8","article-title":"Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study","volume":"15","author":"Ribas","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2026.114669_bib3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","article-title":"Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial","volume":"5","author":"Ascierto","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2026.114669_bib4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1755-148X.2011.00950.x","article-title":"Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition","volume":"25","author":"Deng","year":"2012","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.isci.2026.114669_bib5","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ccell.2015.03.008","article-title":"Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1\/FAK signaling","volume":"27","author":"Hirata","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.114669_bib6","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/onc.2013.131","article-title":"MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines","volume":"33","author":"Vultur","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2026.114669_bib7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.114669_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nm.4472","article-title":"Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF\/MEK inhibitors","volume":"24","author":"Boshuizen","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.114669_bib9","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.114669_bib10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.114669_bib11","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1038\/cdd.2016.96","article-title":"Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM","volume":"23","author":"Rohrbeck","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.isci.2026.114669_bib12","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1172\/JCI65780","article-title":"Melanoma adapts to RAF\/MEK inhibitors through FOXD3-mediated upregulation of ERBB3","volume":"123","author":"Abel","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.114669_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.114669_bib14","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1200\/JCO.19.02630","article-title":"Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W","volume":"38","author":"Chae","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.114669_bib15","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/jnci\/djz245","article-title":"The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design","volume":"112","author":"Flaherty","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.isci.2026.114669_bib16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1755-148X.2010.00685.x","article-title":"PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells","volume":"23","author":"Halaban","year":"2010","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.isci.2026.114669_bib17","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.114669_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26031313","article-title":"Colorectal Cancer: Current and Future Therapeutic Approaches and Related Technologies Addressing Multidrug Strategies Against Multiple Level Resistance Mechanisms","volume":"26","author":"Puzzo","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.114669_bib19","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.1158\/0008-5472.CAN-20-1496","article-title":"Neural crest-like stem cell transcriptome analysis identifies LPAR1 in melanoma progression and therapy resistance","volume":"81","author":"Liu","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.114669_bib20","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/s41587-021-00837-3","article-title":"Variability within rare cell states enables multiple paths toward drug resistance","volume":"39","author":"Emert","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.114669_bib21","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1158\/2159-8290.CD-18-0348","article-title":"ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma","volume":"9","author":"Ojha","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.114669_bib22","doi-asserted-by":"crossref","first-page":"905","DOI":"10.15252\/msb.20166796","article-title":"Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state","volume":"13","author":"Fallahi-Sichani","year":"2017","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.isci.2026.114669_bib23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature22794","article-title":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","volume":"546","author":"Shaffer","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.114669_bib24","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41467-017-00452-4","article-title":"Tumor-associated B-cells induce tumor heterogeneity and therapy resistance","volume":"8","author":"Somasundaram","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.114669_bib25","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1172\/JCI78954","article-title":"Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma","volume":"125","author":"Kwong","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.114669_bib26","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nature14336","article-title":"Therapy-induced tumour secretomes promote resistance and tumour progression","volume":"520","author":"Obenauf","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.114669_bib27","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1177\/2472555220970917","article-title":"Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines","volume":"26","author":"Close","year":"2021","journal-title":"SLAS Discov."},{"key":"10.1016\/j.isci.2026.114669_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.406","article-title":"Silencing FLI or targeting CD13\/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells","volume":"8","author":"Azimi","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.isci.2026.114669_bib29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/2159-8290.CD-12-0386","article-title":"Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma","volume":"3","author":"Girotti","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.114669_bib30","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202215677","article-title":"The AhR-SRC axis as a therapeutic vulnerability in BRAFi-resistant melanoma","volume":"14","author":"Paris","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.isci.2026.114669_bib31","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/sj.bjc.6605714","article-title":"Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy","volume":"102","author":"Paraiso","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.isci.2026.114669_bib32","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.114669_bib33","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1038\/s41467-018-05966-z","article-title":"SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling","volume":"9","author":"Strub","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.114669_bib34","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/2159-8290.CD-13-0424","article-title":"A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors","volume":"4","author":"Konieczkowski","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.114669_bib35","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/ncomms6712","article-title":"Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma","volume":"5","author":"Muller","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.114669_bib36","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1755-148X.2010.00757.x","article-title":"Cancer stem cells versus phenotype-switching in melanoma","volume":"23","author":"Hoek","year":"2010","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.isci.2026.114669_bib37","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1158\/1078-0432.CCR-09-1985","article-title":"Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma","volume":"15","author":"Davies","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.114669_bib38","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1158\/1535-7163.MCT-09-0743","article-title":"Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set","volume":"9","author":"Park","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.isci.2026.114669_bib39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2009.04.012","article-title":"AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer","volume":"16","author":"Vasudevan","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.114669_bib40","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41586-023-06342-8","article-title":"Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells","volume":"620","author":"Goyal","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.114669_bib41","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1074\/mcp.M113.037424","article-title":"Evaluating melanoma drug response and therapeutic escape with quantitative proteomics","volume":"13","author":"Rebecca","year":"2014","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.isci.2026.114669_bib42","doi-asserted-by":"crossref","first-page":"110257","DOI":"10.18632\/oncotarget.22628","article-title":"Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells","volume":"8","author":"Fisher","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2026.114669_bib43","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","article-title":"Toward Minimal Residual Disease-Directed Therapy in Melanoma","volume":"174","author":"Rambow","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.114669_bib44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.114669_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246214","article-title":"The Hippo Signaling Pathway in Cancer: A Cell Cycle Perspective","volume":"13","author":"Xiao","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.114669_bib46","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1021\/ja208518u","article-title":"Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes","volume":"134","author":"Shi","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.isci.2026.114669_bib47","doi-asserted-by":"crossref","first-page":"535","DOI":"10.18632\/oncotarget.27462","article-title":"Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib","volume":"11","author":"Montenegro","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2026.114669_bib48","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.celrep.2017.10.021","article-title":"A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma","volume":"21","author":"Krepler","year":"2017","journal-title":"Cell Rep."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226000441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226000441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:29:09Z","timestamp":1791336549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226000441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2589004226000441"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.114669","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dasatinib resensitizes BRAF\/MEK inhibitor efficacy in patient-derived xenografts from patients with progression on BRAF\/MEK inhibitor treatment","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.114669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114669"}}